Biography
Ryo Morimoto obtained his M.D. from the Faculty of Medicine at The University of Tokyo in 2011, followed by two years of clinical residency in teaching hospitals. In 2017, he completed his Ph.D. in Biochemistry from the Department of Molecular Biology and Biochemistry at the Graduate School of Medicine, The University of Tokyo. His doctoral research focused on lipidomics, specifically investigating phospholipids and lipid mediators.
Following his Ph.D., he joined the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, Germany, as a post-doctoral fellow. From 2017 to 2024, he investigated the diversification of anticipatory antigen receptors in the alternative adaptive immunity of jawless vertebrates (lampreys) and explored their implications for the human adaptive immune system. His work also delved into the evolutionary emergence of lymphopoietic microenvironments and mechanisms of self-tolerance to prevent autoimmunity. In 2022, he advanced to the role of Project Leader in the same group.
In May 2024, Ryo Morimoto started his own independent research team as a Group Leader at the Laboratory for Molecular Infection Medicine Sweden (MIMS) in the Department of Molecular Biology at Umeå University.